Chemomab Therapeutics (CMMB) Other Accumulated Expenses (2018 - 2019)
Chemomab Therapeutics posted quarterly Other Accumulated Expenses of $262000.0 for Q4 2019, down 84.64% year-on-year from $1.7 million in Q4 2018, and down 93.02% on a QoQ basis from $3.8 million in Q3 2019.
Chemomab Therapeutics (CMMB) has 2 years of Other Accumulated Expenses data on file, last reported at $262000.0 in Q4 2019.
- For the quarter ending Q4 2019, Other Accumulated Expenses fell 84.64% year-over-year to $262000.0; the trailing twelve-month figure through Dec 2019 stood at $262000.0 (down 84.64% YoY), and the FY2019 full-year result was $262000.0, down 84.64% from the prior year.
- Other Accumulated Expenses for Q4 2019 stood at $262000.0, down from $3.8 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $3.8 million in Q3 2019 and bottomed at $262000.0 in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 262,000.00 |
| Sep 30, 2019 | 3.75 Mn |
| Jun 30, 2019 | 1.62 Mn |
| Dec 31, 2018 | 1.71 Mn |